Ahmad Abu Limon, MD
Endocrinology, Diabetes & Metabolism · East Lansing, MINPI 1881080406
Payments from drug & device makers
Across 57 payments — averaging $85.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$861
- Lilly USA, LLC$758
- Insulet Corporation$683
- Amgen$507
- Bayer$312
- AstraZeneca$274
- plus $1K from 13 others
What the payments were for
- Food & beverage$4,85399%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 9 | $861 |
| Lilly USA, LLC | 8 | $758 |
| Insulet Corporation | 9 | $683 |
| Amgen(2 entities) | 5 | $507 |
| Bayer | 3 | $312 |
| AstraZeneca | 3 | $274 |
| Novo Nordisk | 3 | $240 |
| Medtronic | 2 | $202 |
| Ascendis Pharma Endocrinology Inc | 2 | $198 |
| Xeris Pharmaceuticals, Inc. | 3 | $126 |
| Neurocrine Biosciences, Inc. | 1 | $119 |
| Lexicon Pharmaceuticals, Inc. | 1 | $105 |
| Sanofi-aventis U.S. LLC | 2 | $96 |
| Boehringer Ingelheim | 1 | $81 |
| Madrigal Pharmaceuticals | 1 | $78 |
| Tandem Diabetes Care, Inc. | 1 | $75 |
| Mannkind Corporation | 1 | $65 |
| Pfizer | 1 | $55 |
| Radius Health, Inc. | 1 | $50 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,885 in reported general payments places this provider in the 65th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 98 | $112,467 |
| OzempicSemaglutide | 65 | $96,852 |
| JardianceEmpagliflozin | 63 | $71,021 |
| TrulicityDulaglutide | 43 | $54,360 |
| ProliaDenosumab | 26 | $43,825 |
| RybelsusSemaglutide | 24 | $40,025 |
| FarxigaDapagliflozin Propanediol | 24 | $28,710 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 18 | $28,037 |
| XyostedTestosterone Enanthate | 34 | $20,897 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $15,153 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $14,109 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 16 | $12,185 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $10,323 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $9,745 |
| JanuviaSitagliptin Phosphate | 12 | $9,449 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $758 | $170,902161 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $240 | $140,532102 claims |
| Boehringer IngelheimJardiance | $81 | $71,02163 claims |
| AmgenProlia | $507 | $43,82526 claims |
| AstraZenecaFarxiga | $274 | $28,71024 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $96 | $28,03718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in East Lansing
- Tobias ElseAnn Arbor$3.5M
- Elif OralAnn Arbor$2.9M
- Jamal HammoudFlint$2.6M
- Lowell SchmeltzFarmington Hills$2.3M
- George GrunbergerBloomfield Hills$1.9M
- Richard AuchusAnn Arbor$1.3M
- Ariel BarkanAnn Arbor$553K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
- Abdulsalam Al KassabRochester Hills$351K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.